Alnylam Pharmaceuticals (ALNY) EPS (Basic): 2009-2025
Historic EPS (Basic) for Alnylam Pharmaceuticals (ALNY) over the last 16 years, with Sep 2025 value amounting to $1.91.
- Alnylam Pharmaceuticals' EPS (Basic) rose 319.54% to $1.91 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.31, marking a year-over-year increase of 111.88%. This contributed to the annual value of -$2.18 for FY2024, which is 38.07% up from last year.
- Latest data reveals that Alnylam Pharmaceuticals reported EPS (Basic) of $1.91 as of Q3 2025, which was up 474.51% from -$0.51 recorded in Q2 2025.
- In the past 5 years, Alnylam Pharmaceuticals' EPS (Basic) registered a high of $1.91 during Q3 2025, and its lowest value of -$3.32 during Q3 2022.
- Over the past 3 years, Alnylam Pharmaceuticals' median EPS (Basic) value was -$0.52 (recorded in 2024), while the average stood at -$0.43.
- Data for Alnylam Pharmaceuticals' EPS (Basic) shows a peak YoY increase of 319.54% (in 2025) and a maximum YoY decrease of 292.31% (in 2025) over the last 5 years.
- Quarterly analysis of 5 years shows Alnylam Pharmaceuticals' EPS (Basic) stood at -$2.16 in 2021, then rose by 22.22% to -$1.68 in 2022, then skyrocketed by 35.12% to -$1.09 in 2023, then skyrocketed by 40.37% to -$0.65 in 2024, then soared by 319.54% to $1.91 in 2025.
- Its EPS (Basic) was $1.91 in Q3 2025, compared to -$0.51 in Q2 2025 and -$0.44 in Q1 2025.